Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 23,049 |
|
|||||
| News | - | ||||||
| Day High | 2.3292 | Low High |
|||||
| Day Low | 2.09 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.09 | 4.25% | 2.21 | 15:29:40 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.17 | 2.09 | 2.3292 | 2.21 | 2.12 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 202 | 23,049 | US$ 2.23 | US$ 51,390 | - | 2.09 - 42.40 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:50:54 | 1 | US$ 2.20 | USD |
Genprex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.28M | 1.49M | - | 0 | -30.86M | -20.77 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Genprex News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.23 | 2.50 | 2.09 | 2.20 | 23,232 | -0.02 | -0.90% |
| 1 Month | 3.00 | 3.27 | 2.09 | 2.76 | 37,095 | -0.79 | -26.33% |
| 3 Months | 5.64 | 7.99 | 2.09 | 4.84 | 90,041 | -3.43 | -60.82% |
| 6 Months | 9.076 | 14.796 | 2.09 | 8.83 | 325,775 | -6.87 | -75.65% |
| 1 Year | 32.756 | 42.40 | 2.09 | 20.95 | 412,386 | -30.55 | -93.25% |
| 3 Years | 155.20 | 166.40 | 2.09 | 98.03 | 861,471 | -152.99 | -98.58% |
| 5 Years | 70.40 | 308.80 | 2.09 | 117.67 | 1,275,404 | -68.19 | -96.86% |
Genprex Description
| Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. |
